Trials / Terminated
TerminatedNCT00730262
Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme
A Phase II Study of TLN-4601 in Patients With Glioblastoma Multiforme
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Thallion Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the efficacy and safety of TLN-4601 used to treat patients with Glioblastoma Multiforme(GBM) that recur/progress after receiving first line systemic therapy post surgery/radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TLN-4601 | 14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2010-04-01
- Completion
- 2010-06-01
- First posted
- 2008-08-08
- Last updated
- 2009-12-30
Locations
8 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00730262. Inclusion in this directory is not an endorsement.